<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-055785</identifier>
<setSpec>1695-4033</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Multidrug-resistant tuberculosis in the pediatric age group</dc:title>
<dc:description xml:lang="en">Aims        To study the clinical and epidemiological features in        eight pediatric patients with multidrug-resistant tuberculosis        (MDR-TB) diagnosed from 1994 to 2005 in three hospitals        in Madrid (Spain).        Methods        A retrospective study was performed in patients aged        less than 15 years old with positive culture for multidrugresistant        Mycobacterium tuberculosis and patients with        negative cultures diagnosed after contact with MDR-TB.        Results        Pulmonary tuberculosis was diagnosed in seven patients        and arthritis in one. Fifty percent of the patients were immigrants        and an adult source case was found in four        (50 %). M. tuberculosis was isolated in gastric juice in        four patients and in synovial biopsy in one. In three patients        cultures were negative but these patients had previously        been in contact with MDR-TB. Two strains were resistant        to isoniazid and rifampicin, four were resistant to        isoniazid, rifampicin and streptomycin, one was resistant        to isoniazid, rifampicin, streptomycin and pyrazinamide,        and one was resistant to 11 drugs. Six patients initially received        conventional treatment without improvement. Patients        received therapy for 15 months (range: 12 to 18)        with 3 to 5 drugs according to the sensitivity study. The        following adverse effects were observed: creatine phosphokinase        increase (one patient), tendinitis (one patient),        alteration of visual evoked responses (one patient) and        transitory psychosis (one patient). One patient required        pulmonary lobectomy. All patients responded satisfactorily        to medical treatment. Conclusions        MDR-TB should be suspected in patients not responding        to TB treatment, especially those from countries with        high resistance rates. In patients with negative cultures,        treatment should rely on the results of a sensitivity study        in the adult source case. MDR-TB requires the use of second-        line anti-TB drugs for prolonged periods with possible        toxic effects</dc:description>
<dc:creator>Castillo Martín, F. del</dc:creator>
<dc:creator>Méndez Echevarría, A</dc:creator>
<dc:creator>Rubio Gribble, B</dc:creator>
<dc:creator>García Miguel, M. J</dc:creator>
<dc:creator>Ballesteros Díez, Y</dc:creator>
<dc:creator>García Rodríguez, J</dc:creator>
<dc:creator>Baquero Artigao, F</dc:creator>
<dc:creator>Rojo Conejo, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos        Estudiar las características clínicas y epidemiológicas        de 8 pacientes pediátricos con tuberculosis multirresistente        (TB-MDR) diagnosticados en 3 hospitales de Madrid entre        1994 y 2005.        Métodos        Estudio retrospectivo que incluye pacientes menores de        15 años con aislamiento de Mycobacterium tuberculosis        multirresistente y sin aislamiento que empezaron tras        contacto con TB-MDR.        Resultados        Se diagnosticaron 7 tuberculosis pulmonares y una artritis.        El 50 % eran inmigrantes y en el 50 % se confirmó        contacto con adulto enfermo. Se aisló M. tuberculosis en        jugo gástrico (4) y biopsia sinovial (1). En 3 pacientes no        se consiguió aislamiento, pero se confirmó contacto con        TB-MDR. Dos cepas presentaron resistencia a isoniazida        (H) y rifampicina (R), cuatro a H, R y estreptomicina (S),        una a H, R, S y pirazinamida (Z) y una a 11 fármacos. Seis        pacientes recibieron tratamiento convencional inicial sin        presentar mejoría. Una vez conocida la sensibilidad de la        cepa, se administró tratamiento durante una media de        15 meses (rango: 12-18 meses) con 3-5 fármacos efectivos.        Los efectos secundarios observados fueron: aumento de        creatinfosfocinasa (1), tendinitis (1), alteración de potenciales        visuales (1) y psicosis transitoria (1). Un paciente requirió        lobectomía. Todos los pacientes evolucionaron satisfactoriamente.        Conclusiones        La TB-MDR debe sospecharse en casos con mala evolución,        especialmente si proceden de zonas con altas tasas        de resistencia. En niños enfermos con cultivos negativos        y expuestos a TB-MDR, el tratamiento se realizará según el        estudio de resistencias del caso índice. La resistencia limita        las opciones terapéuticas y conlleva la utilización de fármacos        con posibles efectos tóxicos</dc:description>
<dc:source>An Pediatr (Barc);67(3): 206-211, sept. 2007. tab</dc:source>
<dc:identifier>ibc-055785</dc:identifier>
<dc:title xml:lang="es">Tuberculosis mutirresistente en la edad pediátrica</dc:title>
<dc:subject>^d7399</dc:subject>
<dc:subject>^d14795^s22016</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d14795^s22057</dc:subject>
<dc:subject>^d14798^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d14798^s22016</dc:subject>
<dc:subject>^d999^s22073</dc:subject>
<dc:subject>^d2715</dc:subject>
<dc:subject>^d30997^s22057</dc:subject>
<dc:subject>^d22226</dc:subject>
<dc:subject>^d30997^s22016</dc:subject>
<dc:subject>^d9362^s22001</dc:subject>
<dc:type>article</dc:type>
<dc:date>200709</dc:date>
</metadata>
</record>
</ibecs-document>
